CN107929239B - 阿立哌唑组合物和用于其经皮给药的方法 - Google Patents
阿立哌唑组合物和用于其经皮给药的方法 Download PDFInfo
- Publication number
- CN107929239B CN107929239B CN201711272197.4A CN201711272197A CN107929239B CN 107929239 B CN107929239 B CN 107929239B CN 201711272197 A CN201711272197 A CN 201711272197A CN 107929239 B CN107929239 B CN 107929239B
- Authority
- CN
- China
- Prior art keywords
- group
- pharmaceutical composition
- composition
- aripiprazole
- gum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229960004372 aripiprazole Drugs 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000499 gel Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003623 enhancer Substances 0.000 claims description 7
- 239000003349 gelling agent Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 4
- 239000005639 Lauric acid Substances 0.000 claims description 4
- 235000021360 Myristic acid Nutrition 0.000 claims description 4
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 3
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920002148 Gellan gum Polymers 0.000 claims description 3
- 229920002907 Guar gum Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229920001615 Tragacanth Polymers 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 235000010492 gellan gum Nutrition 0.000 claims description 3
- 239000000216 gellan gum Substances 0.000 claims description 3
- 235000010417 guar gum Nutrition 0.000 claims description 3
- 239000000665 guar gum Substances 0.000 claims description 3
- 229960002154 guar gum Drugs 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 235000007686 potassium Nutrition 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 235000015424 sodium Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 2
- 241000416162 Astragalus gummifer Species 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 229960002900 methylcellulose Drugs 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 11
- 239000007788 liquid Substances 0.000 abstract description 7
- -1 etc.)) Substances 0.000 description 9
- 229920002125 Sokalan® Polymers 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000004907 flux Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000000823 artificial membrane Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940124811 psychiatric drug Drugs 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 235000007586 terpenes Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- SSUBAQORPAUJGD-UHFFFAOYSA-N 1-methylpyrrolidin-2-one;pyrrolidin-2-one Chemical compound O=C1CCCN1.CN1CCCC1=O SSUBAQORPAUJGD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Developing Agents For Electrophotography (AREA)
- Secondary Cells (AREA)
Abstract
本发明公开了液体和凝胶制剂的组合物,其包含以贴片形式经皮给药的阿立哌唑。
Description
本申请是国际申请日为2011年10月20日,中国国家申请号为201180052667.0,发明名称为“阿立哌唑组合物和用于其经皮给药的方法”的发明专利申请的分案申请。
发明领域
本发明涉及药物组合物的经皮给药领域,其具有可接受的体外性能和优良的生物利用度。特别地,本发明的经皮药物组合物包括贴片剂型的阿立哌唑的液体或凝胶。
发明背景
阿立哌唑(ARPZ)是第一种新型的非典型抗精神病药物(第三代)。在生化上,ARPZ是D2族多巴胺受体的部分激动剂1,2。它能有效对抗精神分裂症的阳性和阴性症状3,4。ARPZ是喹啉酮衍生物,为白色晶体粉末,几乎不溶于水,具有低熔点(135-140℃),MW 448,38g/mol和4.54的分配系数。
附图说明
图1:来自于0.5%卡波普971凝胶系统的药物浓度对通过纤维素膜的ARPZ通量的影响;
图2:来自于0.5%卡波普凝胶系统的通过尸体皮肤渗透的5%ARPZ的累计量;图3:在具有增强剂(脂肪酸)的0.5%卡波普凝胶系统中来自于5%ARPZ的通过人类尸体皮肤渗透的药物的累计量。
具体实施方式
实施例1
ARPZ几乎不溶于水并且已被配制为液体和凝胶剂型(表1)。所有被报道的值均为重量/体积百分比(W/V)。
表1:阿立哌唑的液体和凝胶制剂的组合物(5%W/V)
将实验的最佳混合料设计用于筛选制剂变量的水平。预计1%W/V-20%W/V ARPZ液体制剂的最佳组合物具有NMP 40%,DMSO 40%,醇15%和水5%(表1)。凝胶制剂应当包含约0.1%-5%W/V的胶凝剂并且最佳APRZ组合物应当在约1%W/V-20%W/V范围内并具有约.5%W/V的胶凝剂。因此,预测凝胶制剂具有40%的NMP,DMSO 40%,(乙)醇15%,卡波普971 0.5%,和水4.5%(表1)。然而,表2列出了其它的组合,其也能够成功生产根据本发明的液体和凝胶ARPZ制剂。
表2.N-甲基-2-吡咯烷酮(NMP)、二甲基亚砜(DMSO)、乙醇和水在液体阿立哌唑制剂中的浓度范围
除了这些组分,本领域技术人员已知的适用于本发明的其它溶剂可用于制备所述液体制剂,还有它们的组合,包括但不限于,醇类(例如但不限于(甲基、乙基、丁基、丙基、异丙基、肉豆蔻酸异丙酯等))、二醇类(例如但不限于(丙二醇、聚乙二醇、甘油等))、矿物油、植物油等等。
实施例2
评估了胶凝剂和它们的浓度对ARPZ通过人造膜和人类尸体皮肤的渗透的影响并且将两个特征图显示在图1&2中。ARPZ凝胶制剂的最佳的期望的组合物包含0.5%W/V卡波普971。ARPZ可通过胶凝剂凝胶化,所述胶凝剂包括但不限于天然聚合物(例如琼脂、海藻酸和衍生物、决明子、胶原蛋白、明胶、结冷胶、瓜尔豆胶、果胶、钾或钠角叉菜胶、黄蓍胶、黄原胶等)、半合成聚合物(例如甲基纤维素、羧甲基纤维素、羟丙基纤维素、羟丙基甲基纤维素等)合成聚合物(例如羧乙烯聚合物或卡波姆:卡波普940,卡波普934,卡波普971,泊洛沙姆,聚丙烯酰胺,聚乙烯醇,聚乙烯,及其共聚物等)和粘土(例如硅酸盐等)。此外,除了纤维素膜,可在其它人造膜的情况下评估ARPZ,其它人造膜包括但不限于硅橡胶膜(聚二甲基硅氧烷)、脂质体覆盖的膜、固载型液体膜、卵磷脂有机凝胶膜等等。除了ARPZ的凝胶制剂外,还可使用其它的剂型,包括但不限于,软膏、乳膏、乳剂、脂质体等。
实施例3
评估了增强剂对通过人类尸体皮肤的ARPZ的通量的影响并且显示在图3中。ARPZ凝胶制剂的期望的最佳的组合物包含月桂酸和肉豆蔻酸。除了月桂酸和肉豆蔻酸增强剂,所述ARPZ经皮给药可受以下增强剂影响,所述增强剂包括但不限于,水,亚砜,和类似化学药品,二甲基亚砜(DMSO)、二甲基乙酰胺(DMAC)、二甲基甲酰胺(DMF)、癸基甲基亚砜(DCMS)等,氮酮,吡咯烷酮N-甲基-2-吡咯烷酮(NMP),2-吡咯烷酮(2p)等,脂肪酸酯(乙酸丁酯,乙酸乙酯,油酸乙酯,肉豆蔻酸异丙酯,棕榈酸异丙酯,乙酸甲酯等),脂肪酸(癸酸,辛酸,月桂酸,油酸,肉豆蔻酸,亚油酸,硬脂酸,棕榈酸等),醇类,脂肪醇类和二醇类(nathanol,十二烷醇,丙二醇,甘油等),尿素,精油,萜烯和萜类(柠檬烯,麝香草酚,桉叶油素等),脂质体,囊泡,传递体,醇质体等。
实施例4
评估了pH对通过人类尸体皮肤的ARPZ的渗透的影响并且将特征图显示在图2中。ARPZ凝胶经皮制剂的优选的最佳的组合物具有大约6-7的pH。除了这些最佳的pH值,ARPZ经皮给药可能受所述优选范围以外的pH值的影响,但是影响程度更小。因此,依赖于使用的环境,本发明在大约6-7的优选的pH范围以外仍然可能实现。
这里发现的系统可以50mcg/ch-2.h-800mcg/ch-2.h的通量给药ARPZ,其可产生需要疗效的ARPZ血液水平。根据本发明的教导,可通过改变所述参数(例如ARPZ初始浓度、贴片的表面积、制剂的pH、载体组成、增强剂形式和组成等)改变流量。
最佳治疗结果不仅要求合适的药物选择,而且要求有效的给药。严格的定期的药物治疗时间表的治疗精神病的服药依从性非常重要。在许多例子中,由于病人不依从,精神病药物的口服施用与最佳的给药系统相比被考虑的更少5。精神病治疗药物(特别是具有长时间持续作用的药物)的经皮给药在增加的服药依从性中(特别是在老年人口中)将是有价值的。进一步地,ARPZ经皮给药的潜在优势如下:没有猪肝色的首过效应;消除超过剂量或在剂量以下的可能性;通过简单的去除贴片,允许灵活性地终止药物施用;提供了一种简化的治疗方案,因此帮助在老年人口中的服药依从性。
参考文献
1.Inoue,T.,Domae,M.,Yamada,K.,and Furukawa,T.Effects of the novelantipsychotic agent 7-([4-2,3-dichlorophenylo-1-piperazinyl]b Neuroutyloxyo-3,4-dihydro2(1H)-quinolinone(OPC-14597)on prolactin release from the ratanterior pituitary.J.Pharmacol.Exp.Ther.1996;277(1):137-143.
2.Burris,K.D.,Moiski,T.F.,Ryan,E.,Xu,C.,Tottori,K.,Kikuchi,T.,Yocca,F.D,and Molinoff,P.B.Aripiprazole is a high affinity partial agonist at humanD2dopamine receptors.Int.J.Neuropsychopharmacol.2000;3(Suppl.1),S 129.
3.Petrie,J.L.,Saha,A.R.,and McEvoy,J.P.Aripiprazole,a new atypicalantipsychotic:Phase II clinical trial results.Eur.Neuropsychopharm 1997;7(Suppl 2):S227.
4.Saha,A.R.,McQuade,R.,Carson,W.H.,Ali,M.,W.,Durbar,G.C.,andIngenito,G.Efficacy and safety of Aripiprazole and Risperidone vs.Placebo inpatients with schizophrenia and schizoaffective disorder.World J.Biol Psych2001;2(Suppl 1):305S.
5.Geeta,A.,Sanju,D.,Psychotropic Drugs and Transdermal Delivery.AnOverview.Int.J.of Pharma and Bio Science,2001;V 1(2).
Claims (8)
1.一种用于经皮给药的剂型的包含阿立哌唑的药物组合物,其中所述组合物包含:
a)以1-20%w/v的量存在的阿立哌唑;
b)增强剂,其选自由月桂酸和肉豆蔻酸组成的组;
c)0.1%-5%w/v的范围内的胶凝剂,其中所述胶凝剂选自由以下组成的组:琼脂、海藻酸和衍生物、决明子、胶原蛋白、明胶、结冷胶、瓜尔豆胶、果胶、角叉菜胶钠或钾、黄蓍胶、黄原胶、甲基纤维素、羧甲基纤维素、羟丙基纤维素、羟丙基甲基纤维素及其组合;和
d)递送系统,其包含40%w/v N-甲基-2-吡咯烷酮、40%w/v二甲基亚砜、15%w/v醇和5%w/v水,其中所述醇选自由甲醇、乙醇、丁醇、丙醇和异丙醇组成的组;
其中,所述组合物的pH为6至7,并且进一步地,其中,所述组合物为凝胶形式。
2.如权利要求1所述的药物组合物,其进一步包含至少一种赋形剂,所述赋形剂选自由以下组成的组:醇、矿物油和植物油。
3.如权利要求2所述的药物组合物,其中所述醇为选自由丙二醇和聚乙二醇组成的组的二醇。
4.如权利要求1所述的药物组合物,其进一步包含甘油作为赋形剂。
5.一种用于经皮给药的剂型的包含阿立哌唑的药物组合物,其中所述组合物包含:
a)以1-20%w/v的量存在的阿立哌唑;
b)增强剂,其选自由月桂酸和肉豆蔻酸组成的组;
c)0.1%-5%w/v的范围内的胶凝剂,所述胶凝剂选自由以下组成的组:琼脂、海藻酸和衍生物、决明子、胶原蛋白、明胶、结冷胶、瓜尔豆胶、果胶、角叉菜胶钠或钾、黄蓍胶、黄原胶、甲基纤维素、羧甲基纤维素、羟丙基纤维素、羟丙基甲基纤维素及其组合;和
d)递送系统,其包含40%w/v N-甲基-2-吡咯烷酮、40%w/v二甲基亚砜、15%w/v乙醇和5%w/v水;
其中,所述组合物的pH为6至7,并且进一步地,其中,所述组合物为凝胶形式。
6.如权利要求5所述的药物组合物,其进一步包含至少一种赋形剂,所述赋形剂选自由以下组成的组:醇、矿物油和植物油。
7.如权利要求6所述的药物组合物,其中所述醇为选自由丙二醇和聚乙二醇组成的组的二醇。
8.如权利要求5所述的药物组合物,其进一步包含甘油作为赋形剂。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40759110P | 2010-10-28 | 2010-10-28 | |
US61/407,591 | 2010-10-28 | ||
CN201180052667.0A CN103491961B (zh) | 2010-10-28 | 2011-10-20 | 阿立哌唑组合物和用于其经皮给药的方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180052667.0A Division CN103491961B (zh) | 2010-10-28 | 2011-10-20 | 阿立哌唑组合物和用于其经皮给药的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107929239A CN107929239A (zh) | 2018-04-20 |
CN107929239B true CN107929239B (zh) | 2021-06-01 |
Family
ID=45994667
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711272197.4A Expired - Fee Related CN107929239B (zh) | 2010-10-28 | 2011-10-20 | 阿立哌唑组合物和用于其经皮给药的方法 |
CN201180052667.0A Expired - Fee Related CN103491961B (zh) | 2010-10-28 | 2011-10-20 | 阿立哌唑组合物和用于其经皮给药的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180052667.0A Expired - Fee Related CN103491961B (zh) | 2010-10-28 | 2011-10-20 | 阿立哌唑组合物和用于其经皮给药的方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US9138402B2 (zh) |
EP (1) | EP2632463B1 (zh) |
JP (2) | JP5966228B2 (zh) |
CN (2) | CN107929239B (zh) |
AU (1) | AU2011320758B2 (zh) |
BR (1) | BR112013010190B1 (zh) |
CA (1) | CA2816203C (zh) |
ES (1) | ES2675913T3 (zh) |
MX (1) | MX339196B (zh) |
RU (1) | RU2589689C2 (zh) |
WO (1) | WO2012058091A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9757374B2 (en) | 2010-10-28 | 2017-09-12 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
WO2014172344A1 (en) * | 2013-04-16 | 2014-10-23 | Alpha To Omega Pharmaceutical Consultants, Inc. | Pharmaceutical compositions |
US10356018B2 (en) | 2014-01-31 | 2019-07-16 | Vivint, Inc. | User management methods and systems |
CN107920989A (zh) * | 2015-06-08 | 2018-04-17 | 考里安国际公司 | 用于透皮递送阿立哌唑的制剂 |
WO2017025912A1 (en) * | 2015-08-13 | 2017-02-16 | Aequus Pharmaceuticals Inc. | Aripiprazole compositions and methods for its transdermal delivery |
MA44779A (fr) * | 2016-04-25 | 2019-03-06 | Otsuka Pharma Co Ltd | Compositions de produit pharmaceutique comprenant un marqueur d'événement ingérable |
WO2017195897A1 (ja) * | 2016-05-12 | 2017-11-16 | 富士フイルム株式会社 | 経皮製剤 |
JPWO2018117125A1 (ja) * | 2016-12-19 | 2019-08-08 | 富士フイルム株式会社 | 経皮製剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069941A1 (de) * | 2001-03-07 | 2002-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches system zur verabreichung von partiellen dopamin-d2-agonisten |
WO2008041245A2 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and it's process of preparation |
WO2009060473A2 (en) * | 2007-11-06 | 2009-05-14 | Panacea Biotec Limited | Injectable compositions, processes and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101492A0 (en) | 1992-04-03 | 1992-12-30 | Shalom Levy | Anti-skin rash preparation |
JPH0753381A (ja) * | 1993-07-09 | 1995-02-28 | Ciba Geigy Ag | 局所投与可能な亜鉛フタロシアニン組成物 |
DE59509232D1 (de) * | 1994-02-18 | 2001-06-13 | Drossapharm Ag Basel | Transdermales therapeutisches System |
US5558071A (en) * | 1994-03-07 | 1996-09-24 | Combustion Electromagnetics, Inc. | Ignition system power converter and controller |
IL134830A0 (en) * | 2000-03-01 | 2001-05-20 | Chay 13 Medical Res Group N V | Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them |
DE10030716A1 (de) * | 2000-06-23 | 2002-01-03 | Degussa | Tieftemperaturschlagzähe Polymerlegierung |
US20040170672A1 (en) | 2001-03-07 | 2004-09-02 | Thorsten Selzer | Transdermal therapeutic system for administration of partial dopamine-d2 agonists |
CA2428237C (en) | 2003-05-08 | 2010-07-20 | Delmar Chemicals Inc. | Process for the preparation of carbostyril derivatives |
JP4836797B2 (ja) * | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
ATE529409T1 (de) | 2003-12-16 | 2011-11-15 | Teva Pharma | Verfahren zur herstellung von kristallinen aripiprazolformen |
JP2009508859A (ja) | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
BRPI0717171B1 (pt) * | 2006-09-25 | 2023-10-17 | Archer Daniels Midland Company | Material superabsorvente |
US20130084243A1 (en) * | 2010-01-27 | 2013-04-04 | Liliane Goetsch | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
EP2889029A1 (en) * | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
GB0905365D0 (en) * | 2009-03-27 | 2009-05-13 | Norbrook Lab Ltd | A topical parasiticide composition |
EP2238976B1 (en) * | 2009-04-03 | 2012-06-27 | Hexal AG | Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof |
WO2010146872A1 (ja) * | 2009-06-19 | 2010-12-23 | 株式会社メドレックス | アリピプラゾールと有機酸を有効成分とする外用剤組成物 |
US20110028412A1 (en) * | 2009-08-03 | 2011-02-03 | Cappellos, Inc. | Herbal enhanced analgesic formulations |
US9358261B2 (en) * | 2011-10-25 | 2016-06-07 | U.S. Phytotherapy, Inc. | Additional artemisinin and berberine compositions and methods of making |
US9968740B2 (en) * | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
CA2972654A1 (en) * | 2014-12-31 | 2016-07-07 | Valent U.S.A. Llc | Lactofen and dicamba diglycol amine liquid formulations |
-
2011
- 2011-10-20 EP EP11836886.9A patent/EP2632463B1/en active Active
- 2011-10-20 WO PCT/US2011/057080 patent/WO2012058091A2/en active Application Filing
- 2011-10-20 CN CN201711272197.4A patent/CN107929239B/zh not_active Expired - Fee Related
- 2011-10-20 CN CN201180052667.0A patent/CN103491961B/zh not_active Expired - Fee Related
- 2011-10-20 CA CA2816203A patent/CA2816203C/en active Active
- 2011-10-20 BR BR112013010190A patent/BR112013010190B1/pt not_active IP Right Cessation
- 2011-10-20 JP JP2013536677A patent/JP5966228B2/ja active Active
- 2011-10-20 MX MX2013004693A patent/MX339196B/es active IP Right Grant
- 2011-10-20 RU RU2013124401/15A patent/RU2589689C2/ru active
- 2011-10-20 ES ES11836886.9T patent/ES2675913T3/es active Active
- 2011-10-20 AU AU2011320758A patent/AU2011320758B2/en not_active Ceased
- 2011-10-20 US US13/879,485 patent/US9138402B2/en active Active
-
2012
- 2012-11-05 US US13/668,500 patent/US20130171237A1/en not_active Abandoned
-
2016
- 2016-06-16 JP JP2016119741A patent/JP2016164204A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002069941A1 (de) * | 2001-03-07 | 2002-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches system zur verabreichung von partiellen dopamin-d2-agonisten |
WO2008041245A2 (en) * | 2006-10-05 | 2008-04-10 | Panacea Biotec Ltd. | Injectable depot composition and it's process of preparation |
WO2009060473A2 (en) * | 2007-11-06 | 2009-05-14 | Panacea Biotec Limited | Injectable compositions, processes and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
MX339196B (es) | 2016-05-16 |
US9138402B2 (en) | 2015-09-22 |
CN103491961B (zh) | 2018-01-02 |
EP2632463B1 (en) | 2018-04-04 |
EP2632463A2 (en) | 2013-09-04 |
US20130209552A1 (en) | 2013-08-15 |
RU2589689C2 (ru) | 2016-07-10 |
JP2014503479A (ja) | 2014-02-13 |
CN107929239A (zh) | 2018-04-20 |
CA2816203C (en) | 2017-02-21 |
WO2012058091A2 (en) | 2012-05-03 |
RU2013124401A (ru) | 2014-12-10 |
AU2011320758A1 (en) | 2013-05-09 |
JP2016164204A (ja) | 2016-09-08 |
ES2675913T3 (es) | 2018-07-13 |
WO2012058091A3 (en) | 2013-10-17 |
MX2013004693A (es) | 2013-11-01 |
EP2632463A4 (en) | 2016-04-20 |
BR112013010190A2 (pt) | 2016-09-13 |
CA2816203A1 (en) | 2012-05-03 |
JP5966228B2 (ja) | 2016-08-10 |
US20130171237A1 (en) | 2013-07-04 |
BR112013010190B1 (pt) | 2019-12-31 |
CN103491961A (zh) | 2014-01-01 |
AU2011320758B2 (en) | 2015-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107929239B (zh) | 阿立哌唑组合物和用于其经皮给药的方法 | |
CN102176913B (zh) | 外用的他克莫司制剂 | |
JP5144267B2 (ja) | 医薬活性化合物を制御して搬送するための組成物 | |
EP1754491A1 (en) | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist | |
CN104797252B (zh) | 减轻噪音厌恶的兽医方法 | |
KR20130139842A (ko) | 플루르비프로펜을 포함하는 국소성 약학적 조성물 | |
TWI468192B (zh) | 含有二克氯吩鈉(Dichlofenac sodium)之水性貼劑 | |
JP5550339B2 (ja) | シクレソニドを含有する無菌性水性懸濁液 | |
JP3056694B2 (ja) | 新規な治療用抗炎症鎮痛医薬組成物およびその製造法 | |
CN107753419B (zh) | 他克莫司外用制剂 | |
JP2001064206A (ja) | 経皮吸収促進組成物 | |
US9757374B2 (en) | Aripiprazole compositions and methods for its transdermal delivery | |
US20190343796A1 (en) | Composition for external use | |
JP2009196934A (ja) | ニューキノロン系抗菌薬及び乳剤性基剤を含む医薬組成物 | |
KR101894891B1 (ko) | 흡수가 증가된 덱시부프로펜 에멀젼 함유 겔 제형 | |
US10179138B2 (en) | Pharmaceutical composition comprising 7β-hydroxycholesterol intravenous administration | |
CN115518039B (zh) | 一种兽用托芬那酸固体脂质纳米混悬液及其制备方法 | |
WO2021235436A1 (ja) | アポモルヒネ含有経皮吸収型製剤 | |
WO2017025912A1 (en) | Aripiprazole compositions and methods for its transdermal delivery | |
WO2021055273A1 (en) | Anionic polar phospholipid composition and related methods for treatment of mucosal conditions | |
KR20190013535A (ko) | 케토프로펜 함유 반고형 제제 및 그 제조방법 | |
Ahmad et al. | Bioadhesive Vaginal Gels of Novel Antimicrobial Combinations from Herbal Sources. | |
JPWO2009139213A1 (ja) | プロクロルペラジン含有外用医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210208 Address after: New York, USA Applicant after: Alphatti Omega pharmaceutical consulting Co.,Ltd. Address before: British Columbia, Canada Applicant before: Aequus Pharmaceuticals Inc. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210601 Termination date: 20211020 |
|
CF01 | Termination of patent right due to non-payment of annual fee |